Q2 2023 · 13F-HR
Nan Fung Group Holdings Ltdholdings as filed
Filed 2023-08-11 · accession 0001012975-23-000332
$156.5M
Reported value
43
Positions
2023-06-30
Period end
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 48576A100 | — | KARUNA THERAPEUTICS INC | $48.9M | 31.3% | 225,688 | Common | SOLE |
| 452327109 | ILMN | ILLUMINA INC | $22.3M | 14.3% | 119,196 | Common | SOLE |
| 413197104 | HRMY | HARMONY BIOSCIENCES HLDGS IN | $13.0M | 8.29% | 368,665 | Common | SOLE |
| 81181C104 | — | SEAGEN INC | $9.1M | 5.79% | 47,096 | Common | SOLE |
| H5870P102 | OCS | OCULIS HOLDING AG | $8.0M | 5.13% | 651,100 | Common | SOLE |
| 30223G102 | EXAIEUR | EXSCIENTIA PLC | $5.1M | 3.25% | 859,892 | Common | SOLE |
| 46583P102 | — | IVERIC BIO INC | $4.4M | 2.82% | 111,984 | Common | SOLE |
| 98420N105 | XENE | XENON PHARMACEUTICALS INC | $4.4M | 2.81% | 114,380 | Common | SOLE |
| 16961L106 | — | CHINOOK THERAPEUTICS INC | $4.4M | 2.80% | 113,950 | Common | SOLE |
| 76029N106 | REPL | REPLIMUNE GROUP INC | $4.3M | 2.74% | 184,739 | Common | SOLE |
| N5749R100 | 2GH | MERUS N V | $4.0M | 2.54% | 151,000 | Common | SOLE |
| 83444K105 | SLGCUSD | SOMALOGIC INC | $3.9M | 2.50% | 1,696,558 | Common | SOLE |
| 07725L102 | ONC | BEIGENE LTD | $2.1M | 1.37% | 12,022 | Common | SOLE |
| 753018100 | RANI | RANI THERAPEUTICS HLDGS INC | $2.0M | 1.30% | 493,584 | Common | SOLE |
| 45337C102 | INCY | INCYTE CORP | $2.0M | 1.27% | 32,022 | Common | SOLE |
| 36338D108 | GRTX | GALERA THERAPEUTICS INC | $1.9M | 1.22% | 613,223 | Common | SOLE |
| 483497103 | KALV | KALVISTA PHARMACEUTICALS INC | $1.8M | 1.18% | 204,720 | Common | SOLE |
| 69404D108 | PACB | PACIFIC BIOSCIENCES CALIF IN | $1.8M | 1.16% | 136,655 | Common | SOLE |
| 097702104 | BOLT1EUR | BOLT BIOTHERAPEUTICS INC | $1.5M | 0.95% | 1,166,952 | Common | SOLE |
| 374163103 | GERN | GERON CORP | $1.2M | 0.80% | 388,000 | Common | SOLE |
| 30161Q104 | EXEL | EXELIXIS INC | $1.2M | 0.78% | 64,200 | Common | SOLE |
| 09077A106 | BMEA | BIOMEA FUSION INC | $878,000 | 0.56% | 40,000 | Common | SOLE |
| 008064107 | — | AEROVATE THERAPEUTICS INC | $822,102 | 0.53% | 47,936 | Common | SOLE |
| 29384C108 | TRDA | ENTRADA THERAPEUTICS INC | $743,101 | 0.47% | 49,082 | Common | SOLE |
| 270087208 | — | EARGO INC | $729,167 | 0.47% | 147,904 | Common | SOLE |
| 004225108 | ACAD | ACADIA PHARMACEUTICALS INC | $718,117 | 0.46% | 29,984 | Common | SOLE |
| 23306J101 | — | DBV TECHNOLOGIES S A | $704,805 | 0.45% | 370,950 | Common | SOLE |
| 76243J105 | RYTM | RHYTHM PHARMACEUTICALS INC | $660,754 | 0.42% | 40,070 | Common | SOLE |
| 04016X101 | ARGX | ARGENX SE | $557,314 | 0.36% | 1,430 | Common | SOLE |
| 12674W109 | CABA | CABALETTA BIO INC | $530,898 | 0.34% | 41,123 | Common | SOLE |
| 37637K108 | GTLB | GITLAB INC | $353,170 | 0.23% | 6,910 | Common | SOLE |
| 75615P103 | — | REATA PHARMACEUTICALS INC | $336,468 | 0.22% | 3,300 | Common | SOLE |
| 00166B105 | ALXO | ALX ONCOLOGY HLDGS INC | $315,045 | 0.20% | 41,950 | Common | SOLE |
| 09061G101 | BMRN | BIOMARIN PHARMACEUTICAL INC | $313,348 | 0.20% | 3,615 | Common | SOLE |
| 558868105 | MDGL | MADRIGAL PHARMACEUTICALS INC | $273,042 | 0.17% | 1,182 | Common | SOLE |
| N01045108 | — | AFFIMED N V | $222,813 | 0.14% | 372,472 | Common | SOLE |
| 00973Y108 | AKRO | AKERO THERAPEUTICS INC | $206,603 | 0.13% | 4,425 | Common | SOLE |
| 31572Q808 | FGENEUR | FIBROGEN INC | $167,686 | 0.11% | 62,106 | Common | SOLE |
| 50015M109 | KOD | KODIAK SCIENCES INC | $135,392 | 0.09% | 19,622 | Common | SOLE |
| 09058V103 | BCRX | BIOCRYST PHARMACEUTICALS INC | $125,643 | 0.08% | 17,847 | Common | SOLE |
| 00288U106 | ABCL | ABCELLERA BIOLOGICS INC | $80,886 | 0.05% | 12,521 | Common | SOLE |
| 157085101 | CERS | CERUS CORP | $34,863 | 0.02% | 14,172 | Common | SOLE |
| 04746L104 | — | ATHIRA PHARMA INC | $34,719 | 0.02% | 11,769 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.